News
Gilead sets Covid-19 drug candidate remdesivir price at $390 per vial
Gilead Sciences has set the price of its investigational Covid-19 drug remdesivir at $390 per vial for the US and governments of other developed...
Press Releases
GSK receives first regulatory approval for Duvroq in Japan for patients with anaemia due to chronic kidney disease
GlaxoSmithKline plc announced the approval of a Japanese New Drug Application (JNDA) by the Ministry of Health, Labour and Welfare for Duvroq (daprodustat) tablets,...
Clinical Trials
Samsung Bioepis Initiates Phase 3 Clinical Trial for SB15, Proposed Biosimilar to Eylea
Samsung Bioepis announced the initiation of Phase 3 clinical trial for SB15, the company's proposed biosimilar referencing Eylea® (aflibercept). The Phase 3 clinical trial...
Drug Research
Abbott and Tandem Diabetes Care Advance Development of Integrated Technologies for Future Automated Insulin Delivery Systems
Abbott and Tandem Diabetes Care announced that they have finalized an agreement to develop and commercialize integrated diabetes solutions that combine Abbott's world-leading1 continuous...
Clinical Trials
Astrazeneca: Selumetinib granted orphan drug designation in Japan for neurofibromatosis type 1
AstraZeneca announced that selumetinib has been granted orphan drug designation (ODD) in Japan for the treatment of neurofibromatosis type 1 (NF1), a rare and...
News
Stevanato Group: planned investments under the 2020-2023 industrial plan – about 400 million euros to finance the company development
Italy-based Stevanato Group, a leading producer of pharmaceutical glass containers and integrated provider of drug delivery systems, continued its growth in 2019, recording a...
News
Takeda forms $900m research alliance with Carmine Therapeutics
Japanese pharmaceutical giant Takeda Pharmaceutical has entered into a research collaboration agreement with US-based Carmine Therapeutics for the discovery, development and commercialisation of rare...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read